Clinical trial
An Exploratory Study to Investigate the Safety and Efficacy of Ricolinostat for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
NCT05229042 is registered in ClinicalTrials.gov with Beijing 3E-Regenacy Pharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Study to Investigate the Safety and Efficacy of Ricolinostat for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
- Lead sponsor
- Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 1, 2022
- Completion date
- November 10, 2023
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.